This is a phase II multi-center, randomized, double-blind, placebo controlled clinical trial that is evaluating the safety and efficacy of a single dose of parenteral Erythropoietin in patients with acute ST-elevation myocardial infarctions. NIA is the sponsor of this research study, however no subject will be enrolled at the NIA. The study is coordinated by Duke Clinical Research Institute (DCRI) through a Contract with NIA. The study medication is being purchased by the NIA from OrthoBiotech LLC. The study is still ongoing. There have been several serious adverse events that have been reported. These as well as other safety information are periodically reviewed by the Data and Safety Monitoring Board
Povsic, Thomas J; Najjar, Samer S; Prather, Kristi et al. (2013) EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. J Thromb Thrombolysis 36:375-83 |
Najjar, Samer S; Rao, Sunil V; Melloni, Chiara et al. (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305:1863-72 |
Melloni, Chiara; Rao, Sunil V; Povsic, Thomas J et al. (2010) Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J 160:795-803.e2 |